News >

Large Trial Confirms Vismodegib Benefit in Basal Cell Carcinoma

Jason M. Broderick @jasoncology
Published: Tuesday, Jul 19, 2016

Nicole Basset-Seguin, MD, PhD

Nicole Basset-Seguin, MD, PhD

The hedgehog inhibitor vismodegib (Erivedge) had an estimated disease control rate of 92.9% in the STEVIE trial, the largest ever study conducted in advanced basal cell carcinoma, according to results presented at the 2016 ASCO Annual Meeting.

 
Hansson J, Hauschild A, Kunstfeld R, et al. Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts). J Clin Oncol 34, 2016 (suppl; abstr 9532).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x